---
title: "Gilead agrees to $45 million settlement over alleged kickbacks tied to Texas Medicaid"
id: "stat-news-0-stat-gilead-to-pay-45-million-to-settle-kickback-charges-filed-by-texas"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-gilead-to-pay-45-million-to-settle-kickback-charges-filed-by-texas"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/10/22/gilead-settles-kickback-lawsuit-texas-attorney-general/?utm_campaign=rss"
published_at: "2026-10-22T23:12:17.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Gilead agrees to $45 million settlement over alleged kickbacks tied to Texas Medicaid
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-gilead-to-pay-45-million-to-settle-kickback-charges-filed-by-texas
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/10/22/gilead-settles-kickback-lawsuit-texas-attorney-general/?utm_campaign=rss)
- **Published At:** 2026-10-22T23:12:17.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Gilead Sciences agreed to pay $45 million to resolve allegations that it paid kickbacks that affected prescriptions billed to **Texas Medicaid**. - The settlement resolves claims brought by the Texas attorney general, pursued in tandem with a whistleblower lawsuit. - The whistleblower alleged that Gilead paid a third-party firm to hire **registered nurses** who recommended the company’s drugs to patients and prescribers. - Investigators argued that Gilead offered free support services to clinicians to encourage prescriptions, which the state said led to false claims submitted to government programs. - The reporting notes earlier whistleblower suits — nearly a decade old — by Health Choice Advocates and affiliated firms that accused multiple drugmakers of similar practices using third-party nurse contractors. - The source did not provide detailed evidence, contract language, specific timeframes, patient counts, or the precise mechanics of the alleged nurse outreach program. - The article did not report whether Gilead admitted wrongdoing, the settlement’s breakdown, any federal involvement, or related corporate compliance changes following the agreement. - STAT reported that the full story was behind STAT+; the publicly available portion summarized the settlement amount and the core allegations only.
## Clinical Analysis & Structured Key Points
Gilead pays $45 million to settle kickback case filed by Texas AG | STAT Skip to Main Content STAT Plus Pharmalot Gilead to pay $45 million to settle kickback charges filed by Texas attorney general The drugmaker was accused of offering free nursing support services to boost prescriptions Manage alerts for this article Save this story for later Share this article Justin Sullivan/Getty Images By Ed Silverman Oct. 22, 2026 Pharmalot Columnist, Senior Writer Ed Silverman [email protected] Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter . Gilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid program, the latest pharmaceutical company to reach a deal with the state over marketing practices. The state pursued its claims alongside a whistleblower who also filed a lawsuit claiming Gilead paid another company to hire registered nurses to recommend its drugs. The lawsuit also accused Gilead of offering free support services to doctors to prescribe its drugs, which resulted in false claims being filed with government programs. Advertisement Related Story STAT Plus: Texas attorney general sues Sanofi for allegedly providing kickbacks to doctors to prescribe its drugs Nearly a decade ago, Health Choice Advocates and some related firms filed whistleblower lawsuits against several drugmakers, accusing them of hiring third-party contractors to deploy nurses — sometimes by phone, sometimes at patient homes — to ensure that prescriptions were refilled. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Gilead Sciences , kickbacks , legal , Policy , STAT+ Submit a correction request Reprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter . STAT+ Newsletter Pharmalot columnist Ed Silverman rounds up the most important news of the day in the global drug industry Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Service . You may opt out of receiving STAT communications at any time. Recommended Pharmalot Pharmalot October 22, 2026 STAT Plus: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more Pharmalot Pharmalot October 21, 2026 STAT Plus: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more Advertisement Pharmalot Pharmalot October 20, 2026 STAT Plus: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more Pharmalot Pharmalot October 20, 2026 STAT Plus: Launch prices for new medicines dipped slightly last year but remain high, analysis finds Pharmalot Pharmalot October 19, 2026 STAT Plus: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more Subscriber Picks
## Related Clinical Research

- [FDA finalizes guidance on drug-related apps, STAT reports on industry response](https://medichelpline.com/clinical-feed/stat-news-4-stat-fda-finalizes-its-guidance-on-apps-related-to-drugs-pharma-rejoices.md)
- [Medetomidine Appears in Southern California **Fentanyl** Supply: Prevalence, Concentrations, and C](https://medichelpline.com/clinical-feed/medrxiv-1-characterizing-the-emergence-of-medetomidine-in-southern-california-fentanyl.md)
- [Undeclared kratom alkaloids and tianeptine found in products labeled as cat's claw](https://medichelpline.com/clinical-feed/medrxiv-2-undeclared-kratom-alkaloids-and-tianeptine-in-products-labeled-as-cat-s-claw.md)
- [De novo macrocyclic peptides yield potent CXCR4 antagonists for class A GPCRs](https://medichelpline.com/clinical-feed/biorxiv-22-de-novo-macrocyclic-peptide-discovery-produces-potent-class-a-gpcr-ligands-with.md)
- [Rising Costs of Job-Based Health Plans Signal Ongoing Affordability Challenges](https://medichelpline.com/clinical-feed/kff-health-news-0-job-based-health-plan-costs-rise-with-little-relief-in-sight.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.